Antibody-labeled fluorescence imaging of dendritic cell populations in vivo

Ryan J. Cummings*
University of Rochester Medical Center
Department of Microbiology and Immunology
Rochester, New York 14642

Soumya Mitra*
University of Rochester Medical Center
Department of Imaging Sciences
Rochester, New York 14642

Edith M. Lord
University of Rochester Medical Center
Department of Microbiology and Immunology
Rochester, New York 14642

Thomas H. Foster
University of Rochester Medical Center
Department of Imaging Sciences
Rochester, New York 14642

Abstract. We report an optical molecular imaging technique that exploits local administration of fluorophore-conjugated antibodies and confocal fluorescence microscopy to achieve high-contrast imaging of host cell populations in normal and tumor tissue in living mice. The method achieves micron-scale spatial resolution to depths greater than 100 μm. We illustrate the capabilities of this approach by imaging two dendritic cell populations in the skin and normal and tumor vasculature in vivo. © 2008 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.2966122]

Keywords: in vivo imaging; immune cell imaging; confocal microscopy.

Recently, we demonstrated a fresh whole-mount immunolabeling method that enables multicolor imaging of tumor and normal tissue vasculature and lymphatics, host cell populations, and extracellular matrix with minimal perturbation of tissue architecture. Here, we describe the extension of a fluorophore-conjugated-antibody-labeling-based confocal fluorescence imaging method to living mice and use the technique to identify LC and dermal or interstitial DC (iDC) trafficking in normal ear and in an intradermal murine tumor model. Within 2 h after direct intradermal injection of antibody, the method yields images with very high contrast and confocal image resolution to depths of at least 100 μm in living tissue. Excellent staining persists for a minimum of 3 to 6 h following a single injection. Although these two DC populations are labeled using the same antibody directed against the major histocompatibility complex class II (MHC-II), they are distinguished unambiguously on the basis of their distinct morphologies and their stratification in the epidermal and dermal layers of the skin.

Prior to injection of fluorophore-conjugated antibodies, hair on the ears of BALB/c mice was removed by a chemical depilatory agent. One day after hair removal, the mice were anesthetized, and the ears were injected intradermally on the ventral side with 40 μl of an antibody cocktail consisting of phosphate buffered saline (PBS), Fc block (0.35 mg/ml; BD Biosciences, San Diego, California), allophycocyanin (APC)-conjugated anti(α)MHC-II (0.05 mg/ml; eBioscience, Inc., San Diego), and AlexaFluor488-conjugated αCD3 (0.05 mg/ml; Biolegend, San Diego). The first of these antibodies labels the two morphologically distinct yet related antigen-presenting cells—the LCs within the epidermis and...
iDCs in the dermis. The second labels the adhesion molecule PECAM, which is highly expressed on blood vessels and less intensely expressed on lymphatic vessels. Vessels reside only in the dermal layer, and labeling them contributes to the identification of the two DC populations. After 2 h to allow for the unlabeled antibody to clear, the mice were again anesthetized for imaging.

In vivo imaging was performed using a custom inverted laser scanning confocal fluorescence microscope. We have recently reported on the use of the antibody labeling technique in conjunction with the confocal imaging system to visualize the intratumor distribution of a photodynamic therapy sensitizer in vivo with respect to fluorophore-labeled CD31-positive vessels. In this study, to image the two DC populations and CD31-positive vessels, we used sequential two-color excitation of identical fields of view; APC was excited with a 639-nm diode laser, and Alexa488 was excited with 488 nm from an argon-ion laser. The APC and Alexa488 emissions were detected using a 647LP long-pass filter and a 515/30 bandpass filter, respectively. The combination of a 100-μm-diam pinhole and a 10×, 0.45 NA objective gave an...
optical section thickness of approximately 6 μm, as determined by fluorescence edge response measurements. The images were acquired with a lateral resolution of 1 μm per pixel. The mice were placed on the stage in the supine position so that the ventral side of the ear was facing downward for imaging. Confocal images were then acquired every 3 μm, beginning at an initial depth of roughly 30 μm from the surface. The images could then be analyzed individually or as a three-dimensional (3-D) volume. For all experiments, the appropriate isotype controls were used to rule out nonspecific staining.

Confocal fluorescence images obtained in vivo show positive staining for both DC types, as evident by their unique morphologies at depths consistent with their localization in epidermal or dermal layers. Within the epidermis at a depth of approximately 40 μm from the surface of the ear, an extensive mesh-network of densely packed LCs with characteristic long dendritic-like projections is shown in Fig. 1a. Optical sections acquired in the dermis at depths of approximately 80 μm [Fig. 1b] show that the LC population is no longer present and that it is replaced by a stout, relatively sparse iDC population lacking long projections. Also evident in Fig. 1b and exclusive to the dermis is the extensive vasculature system, which is labeled with αCD31 antibody and which serves as a useful biomarker to discriminate dermal from epidermal layers. We note that the iDCs tend to cluster tightly in the vicinity of the vasculature.

To confirm the identification of the DC populations imaged in vivo, we used whole-mount labeling of ex vivo tissues obtained from the dermal and epidermal layers of the ear and conventional fluorescence microscopy. Although both LCs and iDCs are MHC-II positive on their cell surfaces, only the LCs are positive for internal langerin, a C-type lectin unique to the cell and crucial for its development. Briefly, mice were sacrificed, ear hair was chemically removed, and ears were excised and split with the aid of forceps into dorsal and ventral halves. For dermal labeling, split ears were placed in 200 μl of PBS with Fc Block (28.6 μg/ml), APC-conjugated αMHC-II (7.5 μg/ml), and phycoerythrin (PE)-conjugated αCD31 (7.5 μg/ml) and stained for 2 h at 4°C. To label the epidermis exclusively, additional tissue processing was required. Following ear splitting, halves were floated in 0.5 M

---

**Fig. 1** In vivo confocal fluorescence images of an EMT6 tumor 2 h after intradermal injection with fluorophore-conjugated αMHC-II and αCD31. (a) MHC-II+ cells (red) visualized at a depth of ~40 μm in the tumor with morphology consistent with that of Langerhans cells. No CD31-positive vasculature is observed at this depth. (c) Positively stained cells (red) at a depth of ~80 μm in the tumor in the presence of a highly vascularized tumor microenvironment. Images (b) and (d) are expanded views of the region of interest indicated by the white box superimposed on (a) and (c), respectively. Imaging experiments were performed in 4 tumor-bearing mice, and the results were found to be reproducible. The field of view in images (a) and (c) is 800 μm × 800 μm, while that in (b) and (d) is 200 μm × 200 μm.
ammonium thiocyanate at 37°C for 20 min to separate epidermal from dermal layers. The epidermal layer was then fixed in 2% paraformaldehyde at room temperature for 15 min to permeabilize the cells to enable labeling of internal langerin. Epidermal tissue was then incubated for 2 h with PE-conjugated alangerin (7.5 μg/ml) and APC-conjugated αMHC-II (7.5 μg/ml). Positive staining of epidermal whole mounts with both αMHC-II [Fig. 1(c)] and internal alangerin [Fig. 1(d)] confirms the identification of these epidermal LCs. This critical confirmation can be performed only \textit{ex vivo}, as cell permeabilization is not possible \textit{in vivo}. The significant overlap between the images of the cell surface and internal markers for LCs is depicted in Fig. 1(e). Single-color control experiments revealed no detectable cross talk between these two detection channels. The long cellular processes characteristic of these LCs are apparent in both the images obtained from the epidermal whole-mount preparation and from the superficial optical sections \textit{in vivo} [Fig. 1(a)].

\textit{Ex vivo} fluorescence imaging of the dermal layer [Fig. 1(f)] reveals vascular and DC cell morphology features similar to those observed in the images obtained from the deeper, dermal skin layer \textit{in vivo} [Fig. 1(b)].

We have also implemented this technique to examine the tumor microenvironment in EMT6 mammary tumors grown intradermally in the ears of BALB/c mice. Tumors were initiated with an intradermal injection of \(2 \times 10^5\) EMT6 cells and grown to a diameter of approximately 3 mm. MHC-II\(^+\) cells and tumor blood vessels were labeled with APC-conjugated αMHC-II and Alexa488-conjugated αCD31, respectively, using intradermal injection of the antibody cocktail described earlier. As illustrated in Fig. 2, \textit{in vivo} confocal images acquired at two different depths \(2\) h after antibody administration revealed excellent, high-contrast staining of MHC-II\(^+\) cells. Specifically, the signal levels from stained cells observed in Figs. 2(a) and 2(c) are at least four- to eightfold higher than the adjacent background. Images acquired at 40 μm below the surface [Figs. 2(a) and 2(b)] reveal a population of epidermal LCs morphologically similar to those seen in Figs. 1(a) and 1(c). In comparison to the DCs imaged at a comparable depth in the normal ear [Figs. 1(b) and 1(f)], at a depth of 80 μm in the tumor [Figs. 2(c) and 2(d)], the MHC-II\(^+\) cells are more numerous, their distribution is more diffuse, and their morphologies suggest a mixed population that may include not only LCs and iDCs similar to the normal ear but also macrophages. The deeper image also shows the CD31-positive tumor vasculature.

We note that the field of view of the \textit{in vivo} images of Figs. 2(a) and 2(c) is 800 μm \(\times 800\) μm and that antibody labeling of MHC-II and CD31 is efficient across the entire image following a single injection outside the imaging field. Thus, the antibody conjugates diffused laterally a distance of more than 800 μm, which is much greater than the maximum depth at which quality images can be obtained with single-photon excited confocal fluorescence imaging. The method is therefore not limited by the depth of antibody diffusion but rather by attenuation of the excitation light. We note also that both DC populations are fully accessible to our imaging method in the mouse ear. This has been confirmed by successfully imaging CD31-positive vessels at depths of approximately 125 μm, roughly 25 μm beyond the layer where the iDCs are stratified in the normal ear (data not shown).

The ability to image noninvasively specific cell types at high spatial resolution \textit{in vivo} and the availability of a wide variety of fluorescently conjugated antibodies render this technique very attractive for many applications in immunology and tumor biology. A particular advantage of intradermal versus systemic injection\(^8\) is that it requires the use of significantly less antibody, and it can be performed with standard, commercially available antibody preparations with negligible toxicity as compared to that encountered from systemic administration.

\section*{Acknowledgments}

The authors acknowledge support from NIH Grant Nos. CA28332, U9AI067733, and CA68409.

\section*{References}


15. S. Mitra and T. H. Foster, “\textit{In vivo} confocal fluorescence imaging of

\textit{Journal of Biomedical Optics} \textbf{044041-4}

July/August 2008 • Vol. 13(4)